Pharmamarketeer

Rubius begins patient dosing in phase 1/2 trial of RTX?240 to treat r/r locally advanced solid tumors

Rubius Therapeutics, a clinical─stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that the first patient

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl